Dr. Reddy's Laboratories Ltd. (DRREDDY.BO)
-BSE 2,077.65 
38.00(1.80%) 17 May 18:26 SGT
| Prev Close: | 2,115.65 |
|---|
| Open: | 2,119.90 |
|---|
| Bid: | 2,077.65 |
|---|
| Ask: | 2,077.65 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2,070.80 - 2,120.00 |
|---|
| 52wk Range: | 1,528.00 - 2,150.90 |
|---|
| Volume: | 10,920 |
|---|
| Avg Vol (3m): | 16,153 |
|---|
| Market Cap: | 352.85B |
|---|
| P/E (ttm): | 24.42 |
|---|
| EPS (ttm): | 85.08 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in INR.
External Headlines
- Dr Reddy's welcomes new pharma pricing policy@ Business Standard(Sat, 18 May)
- Dr Reddy's says 'have factored in the impact'@ Hindu Business Line(Fri, 17 May)
- DR. REDDY'S LABORATORIES LIMITED : Dr. Reddy's Q4 & FY13 Financial ... - 4@ traders (press release)(Thu, 16 May)
- Lupin gains No 2 slot overtaking Dr Reddy's@ Business Standard(Thu, 16 May)
- Lupin gains No 2 slot overtaking Dr Reddy's@ Business Standard(Thu, 16 May)
- Dr Reddy's Lab extends gains on strong Q4 earnings@ Business Standard(Thu, 16 May)
- Dr. Reddy's Laboratories Limited - Inline performance, outlook no longer ...@ Equity Bulls(Thu, 16 May)
- Dr. Reddy's Earnings Increase Y/Y - Analyst Blog - NASDAQ.com@ NASDAQ(Thu, 16 May)
- Dr. Reddy's Laboratories Limited - Moneycontrol.com@ Moneycontrol.com(Wed, 15 May)
- Dr Reddy's Lab gains on strong Q4 earnings@ Business Standard(Wed, 15 May)
Headlines
- Asia's Best Analyst: Health Careat The Wall Street Journal(Sun, 12 May)
- Dr. Reddy’s Announces the Launch of Zoledronic Acid Injectionat noodls(Thu, 4 Apr)
- Dr. Reddy’s appoints GV Prasad as Chairman and Satish Reddy as Vice-Chairman of the Companyat noodls(Tue, 2 Apr)
- Dr. Reddy’s announces the launch of Zenatane™ (Isotretinoin Capsules USP)at noodls(Fri, 29 Mar)
- Dr. Reddy’s and Nordion Inc. (formerly MDS Inc.) settle claimsat noodls(Mon, 25 Mar)
- [$$] Dr Reddy's Laboratories Founder Anji Reddy Diesat The Wall Street Journal(Sat, 16 Mar)
- Dr. Reddy’s Announces the Launch of Zoledronic Acid Injectionat noodls(Tue, 5 Mar)
- Dr. Reddy’s Q3 & 9 months FY13 Financial Results: Q3 FY13 Revenues at Rs.28.7 billion (YoY growth of 23%); 9 months FY13 Revenues at Rs.82.9 billion (YoY growth of 26%)at noodls(Thu, 14 Feb)
- Dr. Reddy's to release Q3 FY13 results on February 14, 2013 Earnings call slated for February 14, 6.30 PM IST / 8.00 AM EST*at noodls(Mon, 11 Feb)
- Dr. Reddy’s announces the Launch of Desloratadine ODT (Orally Disintegrating Tablets)at noodls(Fri, 1 Feb)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 3.28 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Dr. Reddys Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products.
View More